Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imiloxan SCHEMBL124122 | 0.99 | MEN1 (1.00) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL10931695 | 0.93 | TSHR (0.87) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL11010829 | 0.93 | TSHR (0.87) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL10934612 | 0.93 | CYP1A2 (0.87) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL11010833 | 0.93 | TSHR (0.87) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL10934602 | 0.93 | CYP1A2 (0.87) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL10931689 | 0.93 | TSHR (0.87) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL10932287 | 0.91 | CYP1A2 (0.83) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL10932290 | 0.91 | CYP1A2 (0.83) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 | |
| Imiloxan SCHEMBL10931686 | 0.90 | TSHR (0.81) | CYP1A2CYP3A4CYP2D6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2731606-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | Allergan, Inc. (US) | 2014-05-21 | — | — | EP | claimed |
| CN-103796652-A | Gel compositions of oxymetazoline and methods of use | ALLERGAN INC | 2014-05-14 | — | — | CN | claimed |
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-03-28 | — | — | US | claimed |
| WO-2013038200-A2 | NEURODEVELOPMENTAL DISORDERS | THE UNIVERSITY OF SUSSEX (GB) | 2013-03-21 | — | — | WO | claimed |
| WO-2013010032-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009111031-A2 | METHODS OF TREATING VASOMOTOR SYMPTOMS | INTRA-CELLULAR THERAPIES, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-7550466-B2 | Alpha and/or β-adrenergic antagonists and agonists to treat pain | SUN HEALTH RESEARCH INSTITUTE (US) | 2009-06-23 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | RICHTER VIRGINIA PACT (US) | 2002-03-21 | — | — | US | claimed |
| WO-2001019371-A1 | TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/α2 ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS | RICHTER, REED (US) | 2001-03-22 | — | — | WO | claimed |
| US-6162455-A | Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 2000-12-19 | — | — | US | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-5109007-A | Administering atipamezole and idazoxan | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-04-28 | — | — | US | claimed |
| EP-0047531-B1 | 2-(1,4-BENZODIOXAN-2-YLALKYL) IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1985-06-12 | — | — | EP | claimed |
| US-4497818-A | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antihypertensives and platelet aggregation inhibitors | SYNTEX (U.S.A.) INC. (US) | 1985-02-05 | — | — | US | claimed |
| US-4402967-A | BENZODIOXANYL-SUBSTITUTED IMIDAZOLE | SYNTEX (U.S.A.) INC. (US) | 1983-09-06 | — | — | US | claimed |
| EP-0047531-A1 | 2-(1,4-Benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1982-03-17 | — | — | EP | claimed |
| US-4302469-A | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants | SYNTEX (U.S.A.) INC. (US) | 1981-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | CUTA, PDE3A, PTGIS | CYP1A2 384/4885CYP3A4 2123/4885CYP2D6 3309/4885 |
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | HTR2C, HTR2A, ADRA2C | CYP1A2 407/4885CYP3A4 1684/4885CYP2D6 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.